Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant.

Leuk Lymphoma 2011 Jul 3;52(7):1262-70. Epub 2011 May 3.

Divisione di Ematologia-Trapianto di Midollo Osseo, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

Evidence of long-term response to lenalidomide in heavily pretreated patients with multiple myeloma is lacking. This study sought to assess whether long-term responders exist, long-term responders' characteristics, and predictive factors of a long-term response. One hundred and four patients with multiple myeloma treated with lenalidomide and dexamethasone after ≥2 therapy lines (median, 3) were analyzed. Long-term response was defined as at least a partial response (≥PR) lasting ≥12 months. The overall response rate was 73%, and 80.3% of the responses were achieved within 5 months. The median response was 14.3 months. Patients evaluable for long-term response numbered 87, and a total of 47% were long-term responders. Compared to non-long-term responders, long-term responders had better overall survival, less light-chain multiple myeloma, and higher incidence of t(11;14). Previous allogeneic transplant (alloSCT) and the response quality predicted a long-term response. In conclusion, patients treated with lenalidomide can become long-term responders; alloSCT and response quality predict long-term response.

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2011.564695DOI Listing
July 2011
16 Reads

Publication Analysis

Top Keywords

long-term response
24
multiple myeloma
16
long-term responders
16
patients multiple
12
long-term
12
response
11
treated lenalidomide
8
response quality
8
allogeneic transplant
8
allosct response
8
responders
5
patients
5
multiple
5
evaluable long-term
4
lines median
4
median analyzed
4
response defined
4
t1114 previous
4
analyzed long-term
4
therapy lines
4

References

(Supplied by CrossRef)

Similar Publications